United Therapeutics Corp

UTH

Company Profile

  • Business description

    United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

  • Contact

    1000 Spring Street
    Silver SpringMD20910
    USA

    T: +1 301 608-9292

    E: [email protected]

    https://www.unither.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    1,168

Stocks News & Analysis

stocks

Competition impacting ASX market darling

Shares tumble after results.
stocks

Ask the analyst: Is the market underestimating Bapcor?

This moated ASX company's shares are in a prolonged slump. I quizzed our analyst Angus Hewitt on its management, the potential impact of EVs, and more.
stocks

Is our ASX best idea still attractive after shares surge?

Shares rose over 21% following the results. 

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,751.604.000.05%
CAC 408,006.2233.190.42%
DAX 4021,911.74124.740.57%
Dow JONES (US)44,470.41167.010.38%
FTSE 1008,767.8067.270.77%
HKSE21,417.54104.44-0.49%
NASDAQ19,714.27190.870.98%
Nikkei 22538,801.1714.150.04%
NZX 50 Index12,917.4541.100.32%
S&P 5006,066.4440.450.67%
S&P/ASX 2008,484.001.200.01%
SSE Composite Index3,315.536.64-0.20%

Market Movers